KR20210145226A - 간 질환의 치료에서 사용하기 위한 ghrh 또는 이의 유사체 - Google Patents

간 질환의 치료에서 사용하기 위한 ghrh 또는 이의 유사체 Download PDF

Info

Publication number
KR20210145226A
KR20210145226A KR1020217034940A KR20217034940A KR20210145226A KR 20210145226 A KR20210145226 A KR 20210145226A KR 1020217034940 A KR1020217034940 A KR 1020217034940A KR 20217034940 A KR20217034940 A KR 20217034940A KR 20210145226 A KR20210145226 A KR 20210145226A
Authority
KR
South Korea
Prior art keywords
ghrh
pharmaceutically acceptable
trans
hexenoyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217034940A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 케이. 그린스푼
Original Assignee
더 제너럴 하스피탈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 제너럴 하스피탈 코포레이션 filed Critical 더 제너럴 하스피탈 코포레이션
Publication of KR20210145226A publication Critical patent/KR20210145226A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217034940A 2019-03-29 2020-03-27 간 질환의 치료에서 사용하기 위한 ghrh 또는 이의 유사체 Ceased KR20210145226A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962826284P 2019-03-29 2019-03-29
US62/826,284 2019-03-29
US201962861187P 2019-06-13 2019-06-13
US62/861,187 2019-06-13
PCT/US2020/025180 WO2020205498A1 (en) 2019-03-29 2020-03-27 Ghrh or analogues thereof for use in treatment of hepatic disease

Publications (1)

Publication Number Publication Date
KR20210145226A true KR20210145226A (ko) 2021-12-01

Family

ID=72607731

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217034940A Ceased KR20210145226A (ko) 2019-03-29 2020-03-27 간 질환의 치료에서 사용하기 위한 ghrh 또는 이의 유사체

Country Status (10)

Country Link
US (4) US10799562B1 (https=)
EP (1) EP3947426A4 (https=)
JP (1) JP2022527190A (https=)
KR (1) KR20210145226A (https=)
CN (1) CN113646327A (https=)
AU (1) AU2020253828A1 (https=)
CA (1) CA3133319A1 (https=)
IL (1) IL286703A (https=)
SG (1) SG11202110469PA (https=)
WO (1) WO2020205498A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110469PA (en) 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease
CN115884783A (zh) * 2020-07-05 2023-03-31 瑟瑞技术公司 Ghrh类似物的低剂量药物组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678083A (zh) * 2007-04-04 2010-03-24 瑟瑞技术公司 Ghrh分子的药物制剂
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20150174207A1 (en) * 2013-12-24 2015-06-25 University Of Miami Methods for treating cancer with ghrh agonists
US20170105996A1 (en) * 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
WO2017181277A1 (en) * 2016-04-19 2017-10-26 Griffon Pharmaceuticals Inc. Pegylated bioactive peptides and uses thereof
KR20200121308A (ko) * 2018-02-14 2020-10-23 루모스 파마, 인크. 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물
SG11202110469PA (en) * 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease
WO2022093757A1 (en) * 2020-10-30 2022-05-05 The General Hospital Corporation Kits, reagents and methods for the assessment of liver diseases
US20220152012A1 (en) * 2020-11-16 2022-05-19 The Regents Of The University Of California Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof

Also Published As

Publication number Publication date
US10946073B2 (en) 2021-03-16
US11738066B2 (en) 2023-08-29
US10799562B1 (en) 2020-10-13
EP3947426A4 (en) 2023-01-04
WO2020205498A1 (en) 2020-10-08
EP3947426A1 (en) 2022-02-09
JP2022527190A (ja) 2022-05-31
US20240091316A1 (en) 2024-03-21
US20200405816A1 (en) 2020-12-31
CN113646327A (zh) 2021-11-12
AU2020253828A1 (en) 2021-10-28
US12233107B2 (en) 2025-02-25
SG11202110469PA (en) 2021-10-28
IL286703A (en) 2021-10-31
US20210177943A1 (en) 2021-06-17
US20200306345A1 (en) 2020-10-01
CA3133319A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
US12233107B2 (en) GHRH or analogues thereof for use in treatment of hepatic disease
GB2478849A (en) Improved pharmecutical compositions and methods of delivery
KR102377742B1 (ko) 암치료약
Tao et al. Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea
US9308235B2 (en) Treatment of primary and metastatic carcinoma
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
US11857529B2 (en) Methods for treating melanoma
US20090186000A1 (en) Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
SG11202112061RA (en) Bisfluoroalkyl-1,4-benzodiazepin one compounds for treating notch-activated breast cancer
EP3380615A1 (en) Il-34 antisense oligonucleotides and methods of using same
CN118742305A (zh) 用于治疗疾病的口服奥曲肽
Yi et al. Beneficial effect of recombinant human growth hormone on the intestinal mucosa barrier of septic rats
EP4653014A1 (en) Biliary tract cancer treatment agent
EP4643862A1 (en) Pharmaceutical composition and use thereof
US20150023920A1 (en) Novel compositions and methods for preventing or treating cancer metastasis
EP4658785A1 (en) Methods for reducing the risk of major adverse cardiovascular events in primary prevention subjects
WO2025233516A1 (en) Method of increasing time to second progression and time to first subsequent chemotherapy
WO2024231275A1 (en) Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
CN117715643A (zh) 用尼拉帕尼治疗转移性去势抵抗性前列腺癌
Bavec Insulin, Other Hypoglycaemic Drugs, and Glucagon
CN115884783A (zh) Ghrh类似物的低剂量药物组合物及其用途
HK40073572B (zh) 酒精性肝炎的治疗
HK1129840A (en) Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601